TY - JOUR
T1 - Cancer management during the COVID-19 world pandemic
AU - Sobhani, Navid
AU - Mondani, Giuseppina
AU - Roviello, Giandomenico
AU - Catalano, Martina
AU - Sirico, Marianna
AU - D’Angelo, Alberto
AU - Scaggiante, Bruna
AU - Generali, Daniele
N1 - Funding Information:
We would like to acknowledge the support of Mednote, a spin-off program affiliated with the University of Trieste's Mozart Program, for funding this research. We also express our gratitude to Laura L. Russell, Scientific Editor at the Research Medical Library, for her valuable editorial assistance.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023
Y1 - 2023
N2 - Since 2019, the world has been experiencing an outbreak of a novel beta-coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2. The worldwide spread of this virus has been a severe challenge for public health, and the World Health Organization declared the outbreak a public health emergency of international concern. As of June 8, 2023, the virus' rapid spread had caused over 767 million infections and more than 6.94 million deaths worldwide. Unlike previous SARS-CoV-1 and Middle East respiratory syndrome coronavirus outbreaks, the COVID-19 outbreak has led to a high death rate in infected patients; this has been caused by multiorgan failure, which might be due to the widespread presence of angiotensin-converting enzyme 2 (ACE2) receptors—functional receptors of SARS-CoV-2—in multiple organs. Patients with cancer may be particularly susceptible to COVID-19 because cancer treatments (e.g., chemotherapy, immunotherapy) suppress the immune system. Thus, patients with cancer and COVID-19 may have a poor prognosis. Knowing how to manage the treatment of patients with cancer who may be infected with SARS-CoV-2 is essential. Treatment decisions must be made on a case-by-case basis, and patient stratification is necessary during COVID-19 outbreaks. Here, we review the management of COVID-19 in patients with cancer and focus on the measures that should be adopted for these patients on the basis of the organs or tissues affected by cancer and by the tumor stage.
AB - Since 2019, the world has been experiencing an outbreak of a novel beta-coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2. The worldwide spread of this virus has been a severe challenge for public health, and the World Health Organization declared the outbreak a public health emergency of international concern. As of June 8, 2023, the virus' rapid spread had caused over 767 million infections and more than 6.94 million deaths worldwide. Unlike previous SARS-CoV-1 and Middle East respiratory syndrome coronavirus outbreaks, the COVID-19 outbreak has led to a high death rate in infected patients; this has been caused by multiorgan failure, which might be due to the widespread presence of angiotensin-converting enzyme 2 (ACE2) receptors—functional receptors of SARS-CoV-2—in multiple organs. Patients with cancer may be particularly susceptible to COVID-19 because cancer treatments (e.g., chemotherapy, immunotherapy) suppress the immune system. Thus, patients with cancer and COVID-19 may have a poor prognosis. Knowing how to manage the treatment of patients with cancer who may be infected with SARS-CoV-2 is essential. Treatment decisions must be made on a case-by-case basis, and patient stratification is necessary during COVID-19 outbreaks. Here, we review the management of COVID-19 in patients with cancer and focus on the measures that should be adopted for these patients on the basis of the organs or tissues affected by cancer and by the tumor stage.
KW - Cancer management
KW - COVID-19 outbreak
KW - Immune system
KW - Infection
KW - mRNA vaccines
KW - SARS-CoV-2
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85169069303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85169069303&partnerID=8YFLogxK
U2 - 10.1007/s00262-023-03524-1
DO - 10.1007/s00262-023-03524-1
M3 - Review article
C2 - 37642709
AN - SCOPUS:85169069303
SN - 0340-7004
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
ER -